Navigation Links
Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
Date:10/23/2007

HAYWARD, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) presented updated data today from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated antitumor activity and tolerability in patients with solid tumors. KOS-1584/R1645 showed signs of activity in patients with non-small cell lung, ovarian, breast, prostate, pancreatic, head and neck and colon cancer. The Phase 1 trial explored two different schedules of KOS-1584/R1645 using escalating doses. Data reported today were from a trial investigating weekly dosing schedules (weekly 2 weeks out of 3 weeks and weekly 3 weeks out of 4 weeks). Common toxicities were generally low-grade and manageable.

Data from the Phase 1 trial of KOS-1584/R1645 were presented in a poster titled, "Optimization of the Phase 2 Dose of KOS-1584 (a Novel, Synthetic Epothilone) via Weekly Administration," by Howard Burris, M.D., Sarah Cannon Research Institute, Nashville, TN, at the 2007 Annual Meeting of the American Association for Cancer Research/National Cancer Institute/European Organization for Research and Treatment of Cancer (AACR/NCI/EORTC).

"We believe that KOS-1584 has the potential to achieve best-in-class status in the emerging epothilone market as well as to compete in the established taxane market," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "We look forward to our planned commencement of a Phase 2 clinical program for KOS-1584 toward the end of 2007."

Phase 1 Trial Results of KOS-1584

The Phase 1 trial was designed to define the maximum tolerated dose, dose-limiting toxicity and recommended Phase 2 dose and to
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- MHG ... provider, has launched its Medical Equipment and ...  These services are tailored to the cruise industry,s ... prompted industry operators to propose that they should ... Medical,s new program is intended to create standardized ...
(Date:7/29/2014)... July 29, 2014 According to ... "Orthopedic Trauma Fixation Devices Market - Global Forecast, Market ... the global orthopedic trauma fixation devices market is estimated ... to grow at a CAGR of 7.2% from 2014 ... 9.3 billion in 2020. Browse the Orthopedic ...
(Date:7/29/2014)... LAKE CITY and ... -- EastGate Acquisitions Corporation (OTCBB: ESAQ), an ... in the development of improved novel formulations ... active molecules announces expansion of its pharmaceutical ... new development direction includes large molecule drugs that ...
Breaking Medicine Technology:MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4
... 13, 2011 CVS Caremark Corporation (NYSE: ... president and chief financial officer of CVS Caremark, will ... 2011 Global Consumer Conference on June 22, 2011. Mr. ... (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO ) An ...
... 13, 2011 AmbiCom Holdings, Inc. (OTCQB: ABHI), a ... equipment suppliers, today announced that it has signed an ... Technology, Inc. ("ATI") subsidiary and E-Care Technology Corporation, ("ECT") ... runs for a period of three years. ...
Cached Medicine Technology:CVS Caremark to Present at the Jefferies 2011 Global Consumer Conference 2AmbiCom Forms Joint Alliance With E-Care Technology Corporation 2AmbiCom Forms Joint Alliance With E-Care Technology Corporation 3
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
(Date:7/29/2014)... According to a July 22, 2014 ... “From Kim’s Butt to Angelina’s Lips: The Plastic Surgery ... the celebrity feature most requested by women seeking cosmetic ... Jennifer Lawrence’s nose, and Angelina Jolie’s ... data collected by an online community focused on plastic ...
(Date:7/29/2014)... York, New York (PRWEB) July 29, 2014 ... on behalf of individuals who allegedly suffered serious ... medications continue to move forward in a multidistrict ... of Pennsylvania, Bernstein Liebhard LLP reports. According to ... revised certain deadlines pertaining to bellwether case ...
(Date:7/29/2014)... 2014 Avenidas is always looking ... Once again, the non-profit agency is doing just that with ... seniors. , This event gives seniors the opportunity to learn ... There will be a variety of fun activities, including a ... demonstrations and artists. In addition, there will be food tastings, ...
(Date:7/29/2014)... Virginia Commonwealth University School of Medicine researchers have ... against the debilitating and potentially deadly tick-transmitted disease, ... several years, experts have seen a steady rise ... tick-transmitted bacterial pathogens making the need for ... knowing what to target to prevent disease, and ...
Breaking Medicine News(10 mins):Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 3
... ALEXANDRIA, Va., Oct. 8 The National,Community Pharmacists ... two-term incumbent representing Illinois, for re-election to the,U.S. ... CEO of NCPA,issued the following statement:, "Senator ... and,America,s community pharmacies and the patients they serve. ...
... Pharmacists Association (NCPA) is endorsing Sen. Gordon Smith,(R-OR), ... the,U.S. Senate. Bruce Roberts, RPh, executive vice president ... "Senator Gordon Smith is a powerful advocate for ... serve. That is why the National,Community Pharmacists Association ...
... Inc. (OTCPK:,SNDY) is pleased to announce that the Company ... ending June 30, 2008. Revenues,generated through the first six-months ... comparable period in 2007. The Company,saw an increase in ... just,over $8,000 at the end of fiscal year 2007., ...
... are no safe substitutes for authentic,FDA approved injectables, ... and counterfeit cosmetic injectables are a threat to ... for Injectable Safety. "The,growing acceptance of cosmetic injections ... with consumer cautions," says Coalition,leader, plastic surgeon Jeffrey ...
... Extreme heat events (EHE), or heat waves, are the ... United States, responsible for more deaths annually than hurricanes, ... other climate-related changes in the worldwide environment that directly ... of the American Journal of Preventive Medicine . ...
... Kong Celebrates a Wealth of Innovative Products, HONG ... leader in,research and development, announces today that it will ... 2008 at Gordon Wu Hall, B P,International House to ... in 1902 in Minnesota, United States, 3M has an ...
Cached Medicine News:Health News:Solos Endoscopy, Inc. Posts First Six Months Financials of 2008 on Pinksheets.com 2Health News:Illegal Botox Scammers a Public Threat 2Health News:Illegal Botox Scammers a Public Threat 3Health News:Illegal Botox Scammers a Public Threat 4Health News:Illegal Botox Scammers a Public Threat 5Health News:Climate change will affect public health -- a call to action 2Health News:Climate change will affect public health -- a call to action 3Health News:3M Innovation Day 2Health News:3M Innovation Day 3
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
20 GA TITANIUM RETINAL FORCEPS...
Medicine Products: